title: Low incidence of cancer after venous thromboembolism: An update from the French OPTIMEV Cohort.
abstract: BACKGROUND
  Recent studies have shown lower rates of cancer following venous thromboembolism (VTE) than previously described.
  
  
  OBJECTIVE
  To reassess the risk of cancer in patients with clinical symptoms of VTE with or without confirmed VTE.
  
  
  METHODS
  We used data from OPTIMEV, a French prospective multicenter observational study of patients presenting to hospital and community vascular medicine specialists with suspected VTE. Patients with confirmed VTE (1565) and matched controls without VTE (1847) were followed for 3 years (2006-2009). The main outcome was occurrence of cancer at 3 years, and death was a censoring event.
  
  
  RESULTS
  A total of 5.0% [4.0-6.3] of patients with VTE and 3.8% [3.0-4.9] without VTE developed cancer during follow-up. The adjusted hazard ratio (HR) was 1.2 [0.9-1.8] for patients with confirmed VTE (P=0.22). The overall standardized incidence ratio (SIR) was 1.4 [1.1-1.6] for our population, VTE+ and VTE-, compared with the general population, statistically significant (P<0.05).
  
  
  CONCLUSIONS
  We found a lower occurrence of cancer after VTE than previously described, with no significant difference between patients whether VTE was confirmed or not. Our results (low incidence and no difference between patients VTE+ or VTE-) provide no argument in favor of an extensive screening for cancer in case of VTE.
authors.affiliation: Grenoble Alpes University, TIMC-IMAG, UMR 5525, 38043 Grenoble, France; Geneva University Hospital, Division of Angiology and Hemostasis, CH-1211 Geneva 14, Switzerland.
authors.forename: A-C
authors.initials: AC
authors.lastname: Arnoult
authors.affiliation: Grenoble Alpes University, TIMC-IMAG, UMR 5525, 38043 Grenoble, France; Grenoble University Hospital, Department of Vascular Medicine, 38043 Grenoble, France.
authors.forename: G
authors.initials: G
authors.lastname: Pernod
authors.affiliation: Grenoble Alpes University, TIMC-IMAG, UMR 5525, 38043 Grenoble, France; Grenoble University Hospital, Clinical Research Center, 38043 Grenoble, France.
authors.forename: C
authors.initials: C
authors.lastname: Genty
authors.affiliation: Montpellier University Hospital, Clinical Research Center, Department of Internal Medicine, 34090 Montpellier, France.
authors.forename: J-P
authors.initials: JP
authors.lastname: Galanaud
authors.affiliation: Grenoble University Hospital, Isère Cancer Registry, 38043 Grenoble, France.
authors.forename: M
authors.initials: M
authors.lastname: Colonna
authors.affiliation: Grenoble Alpes University, TIMC-IMAG, UMR 5525, 38043 Grenoble, France; Amiens University Hospital, Department of Vascular Medicine, 80000 Amiens, France.
authors.forename: M-A
authors.initials: MA
authors.lastname: Sevestre
authors.affiliation: Grenoble Alpes University, TIMC-IMAG, UMR 5525, 38043 Grenoble, France; Grenoble University Hospital, Clinical Research Center, 38043 Grenoble, France. Electronic address: Jean-Luc.Bosson@imag.fr.
authors.forename: J-L
authors.initials: JL
authors.lastname: Bosson
mesh_terms: D000368:Aged; D015331:Cohort Studies; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology*; D011446:Prospective Studies; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000453:epidemiology*
keywords: Cancer screening; Deep vein thrombosis; Dépistage cancer; Epidemiological studies; Facteurs de risque; Maladie thromboembolique veineuse; Risk factors; Thrombose veineuse profonde; Venous thromboembolism; Épidémiologie